1 / 76

HIV II

HIV II. Update on Opportunistic Infections Prevention and Treatment. Pathophysiology . Depletion of CD-4 cells (T-helper) HIV binds Cell entry cell death. Direct mechanisms Accumulation of unintegrated viral DNA Interference with cellular RNA processing

don
Download Presentation

HIV II

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV II Update on Opportunistic Infections Prevention and Treatment

  2. Pathophysiology • Depletion of CD-4 cells (T-helper) • HIV binds • Cell entry • cell death

  3. Direct mechanisms Accumulation of unintegrated viral DNA Interference with cellular RNA processing Intracellular gp 120-CD4 autofusion events Loss of plasma membrane integrity because of viral budding Elimination of HIV-infected cells by virus-specific immune responses Indirect mechanisms Aberrant intracellular signaling events Syncytium formation Autoimmunity Superantigenic stimulation Innocent bystander killing of viral antigen-coated cells Apoptosis Inhibition of lymphopoiesis CD4-deficiency

  4. CD4 depletion syndromes • HIV/AIDS • idiopathic CD4+ T lymphocytopenia • Iatrogenic • Corticosteroids • Immunosuppresants

  5. Opportunistic infections • For patients taking potent combination antiretroviral therapy (ART), beginning in 1996, there has been a dramatic decline in the incidence of AIDS-related opportunisticinfections (OIs) such as Pneumocystis carinii pneumonia (PCP), disseminated Mycobacterium avium complex (MAC), and invasive cytomegalovirus (CMV) disease

  6. Treatment Guidelines • 2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV • Treatment of Tuberculosis - June 20, 2003

  7. A Both strong evidence for efficacy and substantial clinical benefit support recommendation for use. Should always be offered. B Moderate evidence for efficacy -- or strong evidence for efficacy but only limited clinical benefit -- supports recommendation for use. Should generally be offered. C Evidence for efficacy is insufficient to support a recommendation for or against use. Or evidence for efficacy might not outweigh adverse consequences (e.g., drug toxicity, drug interactions) or cost of the chemoprophylaxis or alternative approaches. Optional. D Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should generally not be offered. E Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use. Should never be offered. RatingStrength of the Recommendation Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Clin Infect Dis 1994; 18(3):421.

  8. Quality of evidence supporting the recommendation I Evidence from at least one properly randomized, controlled trial. II Evidence from at least one well-designed clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than one center), or from multiple time-series studies. Or dramatic results from uncontrolled experiments. III Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.

  9. HIV and fever • Disseminated MAC • before HAART, most common cause of FUO in advanced AIDS. • Disseminated histo • bartonellosis • CMV • cryptococcosis

  10. Disseminated FUO Fever, night sweats, weight loss, diarrhea Anemia, elevated alkaline phosphatase GI Visceral pulmonary Localized"immune reconstitution" illnesses biopsies show a granulomatous response lymphadenitis (mesenteric, cervical, thoracic) can mimic Pott's disease with disease presenting in the spine Pulmonary Mycobacterium avium-intracellulare complex (MAC)

  11. Findings Adenopathy Elevated alk phos anemia Diagnosis Blood culture Tissue culture Histopathology Treatment Macrolide + ethambutol + rifabutin Amikacin ciprofloxacin MAC

  12. MAC • Sources • Food • Water • soil • Screening not rec b/c no data for benefit, although predicts disease • No recs for avoidance

  13. MAC prophylaxis • Primary CD4 < 50 until >100 3 mo. (AI) • Clarithromycin • Azithromycin • Rifabutin (not combo-EI) • Exclude TB • DI’s • Secondary for 12 mo and until CD4 no sx and CD4 >100 6 mo (BCx neg) • Macrolide + ethambutol, +/- rifabutin • High dose clarithromycin asso. W/higher mortality (EI) • Clofazimine too many ADR’s (DII) • Restart at CD4 <50-100

  14. Azithromycin not affected by c P450 Protease inhibitors Increase clarithromycin levels Some contraindicated w/rifabutin NNRTIs (efavirenz) Induce clarithromycin metabolism Some contraindicated w/rifabutin Drug Interactions

  15. Manifestations Bacillary angiomatosis (BQ) Lymphadenitis (BH) Hepatosplenic disease (BH) peliosis hepatis GI Brain neuropsych bone B. henselae and B. quintana Treatment Erythromycin Tetracycline deriv. Bartonella

  16. Bartonellosis • HIV-higher incidence • Older cats less likely to transmit • Control fleas • No rec for primary prophylaxis • Consider long-term suppression (C-III)

  17. Risk groups MSM IDU Childcare exposure Test IgG if lower risk group Not IDU/MSM % IgG positive Varies by country CMV

  18. Manifestations FUO pancytopenia CNS Retinitis Blurred vision scotomata field cuts Encephalitis Transverse myelitis Radiculitis pneumonitis GI Gastritis/GU DU colitis CMV

  19. Diagnosis Serology-not helpful Tissue histopathology Molecular diagnostics Antigen PCR Treatment Valganciclovir Ganciclovir 5 mg/kg IV bid × 14-21 days Foscarnet 60 mg/kg IV q8h or 90 mg/kg IV q12h × 14-21 days Cidofovir 5 mg/kg IV weekly × 2 then every other week Implants CMV

  20. Primary Can consider if IgG (+) and CD4 <50 Oral ganciclovir or valganciclovir Regular optho exams Discuss symptoms NOT acyclovir/valacyclovir Secondary Intraocular alone not sufficient Valganciclovir Consider stopping when CD4>100-150 6mo Continue regular f/u CMV-neg or leukopoor irradiated blood if CMV (-) CMVprophylaxis

  21. Cryptosporidium Microsporidiosis Isospora Giardia bacterial enteric infections Salmonella Shigella campylobacter Listeria CMV Cdiff HIV and diarrhea

  22. HIV and diarrhea • Crampy abdominal pain, bloating, and nausea suggest small bowel • Cryptosporidia • Microsporidia • Isospora • Giardia • cyclospora) • MAC. • High-volume, watery diarrhea with weight loss and electrolyte disturbance is most characteristic of cryptosporidiosis • bloody stools with abdominal cramping and fever ( invasive bacterial pathogen) • Clostridium difficile • CMV colitis

  23. Stool studies O&P Trichrome AFB Immunohisto Cdiff Thorough history Medication review Low threshold for flex sig Given the availability of effective treatment; more aggressive evaluation that often includes endoscopy has replaced the less invasive approach. Treatment Antimotility agents Imodium, Lomotil Opium Calcium octreotide HIV and diarrhea

  24. Seek vet care for animals with diarrhea WASH HANDS Travel precautions Bottled beverages Avoid fresh produce Avoid ice Consider prophylaxis or early empiric therapy Cipro 500 qd Bactrim Avoid Reptiles, chicks and ducklings Raw eggs Raw poultry, meat and seafood Unpasteurized dairy products/juices Raw seed sprouts Soft cheeses Deli counters unless can reheat Refrigerated meat spreads Bacterial Enteric InfectionsPrevention

  25. coccidian protozoan (I. belli, C. cayetanensis, and Toxoplasma gondii) 5%-10% of diarrhea in immunocompetent Asymptomatic carriers mammalian hosts-cattle, horses, rabbits, guinea pigs, mice. transmission fecal-oral. Waterborne outbreaks due to contamination of drinking water thick-walled, highly resistant oocyst excysts in stomach sporozoites infect enterocytes and persist at the apical pole of intestinal epithelial cells-microscopic appearance of extracellular, adherent parasite Cryptosporidium

  26. biopsy fecal examination Modifed AFB Immunohisto stains Treatment Azithromycin Paromomycin Octreotide nitazoxanide HAART Clarithromycin/rifabutin work, but no data. Counsel regarding exposure-avoid feces diapers young animals (screen BIII) water boil water when suggested (AI) filters (CIII) oysters bottled (CIII) Cryptosporidiosisprevention

  27. observed initially in intestinal biopsy specimens in 1982 No disease in normal hosts 2 types Enterocytozoon bieneusi, reproduces within enterocytes Encephalitozoon (Septata) intestinalis infects epithelial cells and stromal cells of the lamina propria and causes systemic infection Diagnosis Difficult to see by light microscopy-order trichrome stain Treatment Albendazole (for intestinalis) Atovaquone metronidazole. No recs for prevention Microsporidiosis

  28. Isospora • no other known host • endemic in Brazil, Colombia, Chile, and parts of equatorial Africa and southwest Asia. • seen rarely in normals • fecal-oral route

  29. Immunocompetent watery diarrhea usually clear the infection within about 2 weeks; may persist HIV-chronic high-volume watery diarrhea Detection in stool samples difficult, and concentration or flotation methods. AFB + histologic sections Villus atrophy, eosinophil infiltrates, and disorganization of the epithelium shown better with Giemsa on histo Cipro better than Bactrim Isospora

  30. Cyclospora • first reported in the 1980s • endemic in tropical countries and other areas w/poor standards of hygiene and water purification • severity related to the degree of immunosuppression • Rx Bactrim

  31. Cyclospora • Epidemics attributed to contamination of water supplies, fruits, and vegetables • similar to Cryptosporidium but larger (8 to 10 mum versus 4 to 5 mum) and AFB + • fecal-oral route • intermittent watery diarrhea for 3 > mo. • infect enterocytes and proliferate within a supranuclear parasitophorous vacuole.

  32. PCP histoplasmosis cryptococcosis rhodococcus CMV Pneumococcus 100-fold risk Nontypable H. flu Pseudomonas 40-fold risk Lowest CD4 HHV-8 Coccidiodomycosis HIV and pneumonia

  33. PCP

  34. Symptoms Incidious onset SOB>cough pneumothorax Findings diffuse infiltrates in a perihilar or bibasilar distribution and a reticular or reticulonodular pattern No effusion Elevated LDH SX>>>CXR Normal in 26% Diagnosis Sputum for DFA Sputum cytology BAL for same Histopathology/stains PCP

  35. PCP • TMP 15 mg/kg/d + SMX 75 mg/kg/d po or IV × 21 days in 3-4 divided doses; for outpatient, 2 DS tablets po tid rash, fever, gastrointestinal symptoms, hepatitis, hyperkalemia, leukopenia, and hemolytic anemia • Steroid (pO2 < 70 or A-a gradient > 35) • TMP-dapsone • Clinda/primaquine • Atovaquone • Trimetrexate/folinic acid • Iv Pentam • nausea, infusion-related hypotension, hypoglycemia, hypocalcemia, renal failure, and pancreatitis

  36. CD4<200 or history of oral thrush (AII) CD4%<14 or other OI (BII) Bactrim (AI) DS daily (toxo, bacterial pathogens) SS daily DS TIW (BII) rechallenge if rash (desens) - 70% tolerate PCPprophylaxis

  37. Dapsone Dapsone + pyrimethamine/leucovorin aerosolized pentam (Respirgard II)-pregnancy 1st term atovaquone Other aerosolized Pentam parenteral pentam oral pyrimethamine/ sulfadoxine oral clinda/primaquine trimetrexate PCPprophylaxis All BI All CIII

  38. Stop when CD4>200 for 3 mo. Restart if CD4<200 Stop secondary prophylaxis if CD4>200 unless PCP occurred at higher CD4 Children of HIV mothers need prophylaxis Children with PCP can not stop secondary prophylaxis. PCPprophylaxis

  39. Mississippi valley and Ohio valley + worldwide Normal hosts usually asympto or mild URI-no rx THE MOST common endemic mycosis Pulmonary, mucosal, disseminated or CNS Respiratory culture Blood culture Bone marrow biopsy Urine Ag Some cross reaction More sensitive in dissem disease, esp HIV Rx ampho, itra Histoplasmosis

  40. Clin Chest Med - 01-DEC-1996; 17(4): 725-44

  41. Routine skin testing not predictive Avoid Creating soil/old building dust Cleaning chicken coops Disturbing bird roosts Exploring caves Secondary prophylaxis Itraconazole No data-no rec for stopping Primary Prophylaxis No proven survival benefit Consider in high risk and CD4<100 HistoplasmosisPrevention

  42. Increased mortality with Pneumococcal Increased incidence of Pseudomonas Bactrim and macrolide prophylaxis prevent resp infections, but not rec solely for this reason Maintain normal granulocyte count & IgG Prevention Pneumovax BII rec if CD4>200 No data for CD4<200 Repeat in 5 years Repeat when CD4 >200 Typical CAP

  43. Low threshold of suspicion Lower CD4=atypical presentation Higher mortality Tuberculin skin testing (TST) negative in 40% of patients with disease 4-drug therapy initially Drug interactions major issue Tuberculosis

  44. New guidelines Emphasize DOT and provider responsibility Louis Pasteur once said, "The microbe is nothing...the terrain everything" Reculture at 2 mo of trx Extend if still + and cavitary disease INH--rifapentine once weekly continuation phase (Regimens 1c and 2b) is contraindicated CD4+ cell counts <100/µl should receive daily or three times weekly treatment “paradoxical” flares occur Associated w/HAART Effusions, infiltrates, enlargement of CNS lesions, nodes, fever Steroids used Tuberculosis

More Related